108 related articles for article (PubMed ID: 27959765)
1. TP53 and Histone H3.3 Mutations in Triple-Negative Lower-Grade Gliomas.
Chan AK; Mao Y; Ng HK
N Engl J Med; 2016 Dec; 375(22):2206-2208. PubMed ID: 27959765
[No Abstract] [Full Text] [Related]
2. The clinicopathological and prognostic significance of TP53 alteration in K27M mutated gliomas: an individual-participant data meta-analysis.
Dong C; Yuan Z; Li Q; Wang Y
Neurol Sci; 2018 Jul; 39(7):1191-1201. PubMed ID: 29651718
[TBL] [Abstract][Full Text] [Related]
3. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.
Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A
Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431
[TBL] [Abstract][Full Text] [Related]
4. Histone H3 mutations in pediatric brain tumors.
Liu X; McEachron TA; Schwartzentruber J; Wu G
Cold Spring Harb Perspect Biol; 2014 Apr; 6(4):a018689. PubMed ID: 24691963
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide small noncoding RNA profiling of pediatric high-grade gliomas reveals deregulation of several miRNAs, identifies downregulation of snoRNA cluster HBII-52 and delineates H3F3A and TP53 mutant-specific miRNAs and snoRNAs.
Jha P; Agrawal R; Pathak P; Kumar A; Purkait S; Mallik S; Suri V; Chand Sharma M; Gupta D; Suri A; Sharma BS; Julka PK; Kulshreshtha R; Sarkar C
Int J Cancer; 2015 Nov; 137(10):2343-53. PubMed ID: 25994230
[TBL] [Abstract][Full Text] [Related]
6. Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma.
Subashi E; Cordero FJ; Halvorson KG; Qi Y; Nouls JC; Becher OJ; Johnson GA
J Neurooncol; 2016 Jan; 126(2):243-51. PubMed ID: 26511492
[TBL] [Abstract][Full Text] [Related]
7. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
8. Invited Review: Emerging functions of histone H3 mutations in paediatric diffuse high-grade gliomas.
Kasper LH; Baker SJ
Neuropathol Appl Neurobiol; 2020 Feb; 46(1):73-85. PubMed ID: 31859390
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours.
Haque F; Varlet P; Puntonet J; Storer L; Bountali A; Rahman R; Grill J; Carcaboso AM; Jones C; Layfield R; Grundy RG
Acta Neuropathol Commun; 2017 Jun; 5(1):45. PubMed ID: 28587626
[TBL] [Abstract][Full Text] [Related]
10. K27/G34 versus K28/G35 in histone H3-mutant gliomas: A note of caution.
Leske H; Rushing E; Budka H; Niehusmann P; Pahnke J; Panagopoulos I
Acta Neuropathol; 2018 Jul; 136(1):175-176. PubMed ID: 29766298
[No Abstract] [Full Text] [Related]
11. Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity.
Viotti J; Duplan E; Caillava C; Condat J; Goiran T; Giordano C; Marie Y; Idbaih A; Delattre JY; Honnorat J; Checler F; Alves da Costa C
Oncogene; 2014 Apr; 33(14):1764-75. PubMed ID: 23644658
[TBL] [Abstract][Full Text] [Related]
12. Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation.
Castel D; Kergrohen T; Tauziède-Espariat A; Mackay A; Ghermaoui S; Lechapt E; Pfister SM; Kramm CM; Boddaert N; Blauwblomme T; Puget S; Beccaria K; Jones C; Jones DTW; Varlet P; Grill J; Debily MA
Acta Neuropathol; 2020 Jun; 139(6):1109-1113. PubMed ID: 32193787
[No Abstract] [Full Text] [Related]
13. Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors.
Mangerel J; Price A; Castelo-Branco P; Brzezinski J; Buczkowicz P; Rakopoulos P; Merino D; Baskin B; Wasserman J; Mistry M; Barszczyk M; Picard D; Mack S; Remke M; Starkman H; Elizabeth C; Zhang C; Alon N; Lees J; Andrulis IL; Wunder JS; Jabado N; Johnston DL; Rutka JT; Dirks PB; Bouffet E; Taylor MD; Huang A; Malkin D; Hawkins C; Tabori U
Acta Neuropathol; 2014 Dec; 128(6):853-62. PubMed ID: 25315281
[TBL] [Abstract][Full Text] [Related]
14. The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults.
Feng J; Hao S; Pan C; Wang Y; Wu Z; Zhang J; Yan H; Zhang L; Wan H
Hum Pathol; 2015 Nov; 46(11):1626-32. PubMed ID: 26297251
[TBL] [Abstract][Full Text] [Related]
15. Expression of p53 and prognosis in children with malignant gliomas.
Pollack IF; Finkelstein SD; Woods J; Burnham J; Holmes EJ; Hamilton RL; Yates AJ; Boyett JM; Finlay JL; Sposto R;
N Engl J Med; 2002 Feb; 346(6):420-7. PubMed ID: 11832530
[TBL] [Abstract][Full Text] [Related]
16. Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas.
Sloan EA; Cooney T; Oberheim Bush NA; Buerki R; Taylor J; Clarke JL; Torkildson J; Kline C; Reddy A; Mueller S; Banerjee A; Butowski N; Chang S; Mummaneni PV; Chou D; Tan L; Theodosopoulos P; McDermott M; Berger M; Raffel C; Gupta N; Sun PP; Li Y; Shah V; Cha S; Braunstein S; Raleigh DR; Samuel D; Scharnhorst D; Fata C; Guo H; Moes G; Kim JYH; Koschmann C; Van Ziffle J; Onodera C; Devine P; Grenert JP; Lee JC; Pekmezci M; Phillips JJ; Tihan T; Bollen AW; Perry A; Solomon DA
Acta Neuropathol; 2019 Nov; 138(5):877-881. PubMed ID: 31515627
[No Abstract] [Full Text] [Related]
17. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma.
Nikbakht H; Panditharatna E; Mikael LG; Li R; Gayden T; Osmond M; Ho CY; Kambhampati M; Hwang EI; Faury D; Siu A; Papillon-Cavanagh S; Bechet D; Ligon KL; Ellezam B; Ingram WJ; Stinson C; Moore AS; Warren KE; Karamchandani J; Packer RJ; Jabado N; Majewski J; Nazarian J
Nat Commun; 2016 Apr; 7():11185. PubMed ID: 27048880
[TBL] [Abstract][Full Text] [Related]
18. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.
Karsy M; Guan J; Cohen AL; Jensen RL; Colman H
Curr Neurol Neurosci Rep; 2017 Feb; 17(2):19. PubMed ID: 28271343
[TBL] [Abstract][Full Text] [Related]
19. Histone H3 mutations--a special role for H3.3 in tumorigenesis?
Kallappagoudar S; Yadav RK; Lowe BR; Partridge JF
Chromosoma; 2015 Jun; 124(2):177-89. PubMed ID: 25773741
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution.
Yoshimoto K; Hatae R; Sangatsuda Y; Suzuki SO; Hata N; Akagi Y; Kuga D; Hideki M; Yamashita K; Togao O; Hiwatashi A; Iwaki T; Mizoguchi M; Iihara K
Brain Tumor Pathol; 2017 Jul; 34(3):103-112. PubMed ID: 28447171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
